Capricor Therapeutics. Every tracked FinTwit mention of $CAPR, newest first. 19 mentions since the first on Jul 22, 2025. See the price chart.
May 2026 · 1 mention
May 7
Adam Feuerstein ✡️ — $CAPR is suing NS Pharma, its deramiocel commercial partner. Capricor alleges NS Pharma is not doing enough to prepare for commercial launch + some pricing mishegas.
8K https://t.…↗
March 2026 · 2 mentions
Mar 19
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter:
Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era
$REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX
https://t.co…↗
Mar 10
Adam Feuerstein ✡️ — $CAPR resubmission of the deramiocel application accepted by the FDA. New decision date: Aug. 22.
https://t.co/mWSyyXg8di↗
Wayne Liang — I love finding 10x tickers.
With $10k, you would've made:
$576,000+ on $SMX
$50,000+ on $CAPR
$24,000+ on $IRBT
$30,000+ on $PLRZ
All within 2 weeks.
Once the market is less…↗
Dec 3
Adam Feuerstein ✡️ — On $CAPR, the primary endpoint was not changed. Those alleging otherwise are incorrect. The mean change on the PUL 2.0 endpoint was 1.2 points favoring deramiocel over placebo.
F…↗
Dec 3
Adam Feuerstein ✡️ — Deramiocel improved upper-limb function of Duchenne patients by 1.2 points on a 42-point assessment scale, translating into a 54% slowing of disease progression over one year.
Der…↗
Adam Feuerstein ✡️ — Next week: We will certainly see $CAPR and $NVO study readouts, right?↗
Nov 10
Adam Feuerstein ✡️ — $CAPR no HOPE-3 data tonight with earnings release. Study results "expected in the coming weeks."↗
September 2025 · 3 mentions
Sep 25
Adam Feuerstein ✡️ — $CAPR regulatory update after FDA meeting:
HOPE-3 study primary endpoint unchanged.
https://t.co/26IzYAiMM1↗
Sep 23
Adam Feuerstein ✡️ — $REPL +25% today on the WSJ editorial bashing (again) Vinay Prasad?
Super interesting. Reminder, I will be interviewing Replimune's CEO on stage at the STAT Summit Oct. 15. Joini…↗
Sep 4
Adam Feuerstein ✡️ — Hey folks - FDA has posted more Complete Response Letters, including those sent to $CAPR and $REPL.
My quick read doesn't reveal any issues / deficiencies not previously disclose…↗
August 2025 · 1 mention
Aug 26
Adam Feuerstein ✡️ — The STAT Summit is Oct. 15-16 in Boston. We'd love to see you in the audience this year. To entice, we posted a preliminary agenda, with more speakers to come.
https://t.co/DJjPF…↗
July 2025 · 2 mentions
Jul 31
Adam Feuerstein ✡️ — Are we sure Vinay Prasad’s ouster is positive for biotech?
Some musings in this week's newsletter.
A commonly held view of his three-month tenure running the FDA’s biologics divi…↗
Jul 22
Adam Feuerstein ✡️ — $REPL rejection follows the rejection of $CAPR and $RARE drugs, and the FDA's actions against $SRPT.
CBER Director Vinay Prasad is setting a different tone than his predecessor.↗
— Read our story on the $CAPR HOPE-3 results here:
https://t.co/8ql95NDbaj
Adam Feuerstein ✡️ — $CAPR CEO Linda Marban told me:
“We believe we can answer the issues that were raised by the FDA. We’re going to be submitting these data to the FDA and I don’t really see how th…↗
Dec 3
Adam Feuerstein ✡️ — BREAKING: Capricor $CAPR says its cell therapy improved heart and muscle function in Duchenne patients
The dual outcomes in a Phase 3 study will likely bolster the treatment’s re…↗